TAMPA GENERAL HOSPITAL
🇺🇸United States
New Transcatheter Tricuspid Valve Treatments Offer Hope for High-Risk Cardiac Patients
• Innovative catheter-based treatments for tricuspid regurgitation are providing new options for patients deemed too high-risk for traditional open-heart surgery, with procedures allowing discharge within 2-3 days.
• The Evoque Tricuspid Valve Replacement System, FDA-approved in 2024, is being implemented at Sarasota Memorial Hospital, while Tampa General Hospital completed Florida's first TricValve procedure under an FDA Early Feasibility Study.
• Approximately 1.6 million Americans suffer from tricuspid regurgitation, which can lead to heart failure and other life-threatening complications if left untreated with limited options previously available.
CareDx Showcases Extensive Clinical Evidence for Transplant Monitoring Solutions at ISHLT 2025
• CareDx presented 60 abstracts including 19 oral presentations at the 2025 ISHLT meeting, demonstrating the growing clinical adoption of their transplant monitoring solutions across 92 transplant centers.
• New findings from the SHORE study revealed that HeartCare is prognostic of long-term graft outcomes independent of biopsy results and is being used by clinicians to guide immunosuppression management decisions.
• Data from the ALAMO study showed AlloSure Lung may predict development of Chronic Lung Allograft Dysfunction (CLAD) and effectively monitors acute cellular rejection and treatment response in lung transplant patients.
Orca Bio's Phase III Precision-T Study Shows Promise for Novel T-Cell Immunotherapy in Blood Cancers
• Orca Bio announced positive results from its pivotal Phase III Precision-T study evaluating Orca-T, an investigational allogeneic T-cell immunotherapy for various blood cancers including AML, ALL, and high-risk MDS.
• The innovative therapy utilizes highly purified regulatory T-cells, hematopoietic stem cells, and conventional T-cells derived from matched donors' peripheral blood, representing a potential advancement in blood cancer treatment.
• The study's findings position Orca-T as a promising late-stage candidate in the cellular therapy landscape, potentially offering new options for patients with difficult-to-treat hematologic malignancies.
Study Reveals Gender Gap in Post-Stroke Cardiac Care: Women Receive Less Monitoring and Fewer Cardiology Referrals
• New research from the DiVERT Stroke clinical study shows women experiencing stroke receive significantly fewer cardiology referrals and shorter hospital stays compared to men.
• Analysis of 2,699 patients reveals female patients were less likely to receive post-stroke cardiac monitoring (19.9% vs 23%) despite women having a higher lifetime stroke risk.
• The study demonstrates consistent atrial fibrillation detection rates post-stroke with cardiac monitoring across both genders, highlighting the importance of standardized care pathways.
Targeted Therapies Reshape Treatment Strategies for Mutation-Driven Cancers
• Oral targeted therapies are significantly improving the patient experience by directly addressing actionable mutations, leading to more personalized treatment plans.
• The INAVO120 trial's efficacy and safety data have paved the way for the approval of inavolisib, a PI3Kα-specific inhibitor, offering a more targeted approach.
• Precision medicine is driving the exploration of targeted therapy combinations in earlier lines of treatment, as demonstrated by trials like ELEVATE and CAPItello-292.
• Emerging strategies focus on targeting truncal mutations earlier in treatment to potentially improve outcomes and address the evolving landscape of cancer therapy.
Hemophilia Treatment Advances: Gene Therapy, Prophylaxis, and On-Demand Therapies Highlighted at ASH 2024
• ASH 2024 highlighted significant progress in hemophilia care since Hemlibra's approval, including gene therapies for hemophilia A and B, offering curative potential.
• Despite advances, unmet needs persist, including spontaneous bleeds in prophylaxis patients, limited gene therapy access, and concerns about long-term risks like liver toxicity.
• Emerging therapies like Pfizer's giroctocogene fitelparvovec and Sanofi's fitusiran show promise, with ongoing trials and regulatory reviews potentially expanding treatment options.
• Novel on-demand treatments like Staidson's bemiltenase alfa offer alternatives, particularly in price-sensitive markets, demonstrating a 12-hour bleed clearance rate of 83%.
Trastuzumab Deruxtecan Shows Promise in HER2-Mutated NSCLC
• Trastuzumab deruxtecan (T-DXd) has demonstrated efficacy in patients with previously treated HER2-mutated non-small cell lung cancer (NSCLC).
• The DESTINY-Lung01 trial showed a 55% objective response rate in HER2-mutated NSCLC patients treated with T-DXd at 6.4 mg/kg.
• A lower dose of T-DXd (5.4 mg/kg) was approved by the FDA in 2022 for HER2-mutant NSCLC due to comparable efficacy and reduced toxicity.
• Ongoing research explores the potential of T-DXd as a frontline therapy for HER2-overexpressing or mutated NSCLC.
Enhertu Shows Promise in Frontline HER2-Mutated NSCLC Treatment
• Fam-trastuzumab deruxtecan-nxki (Enhertu) is under investigation as a first-line treatment for HER2-mutated and -overexpressing non-small cell lung cancer (NSCLC).
• The DESTINY-Lung01 trial revealed a 55% objective response rate and a median progression-free survival of 8.2 months in HER2-mutated NSCLC patients.
• Combining ADCs with other agents like immunotherapy or chemoimmunotherapy is being explored, with ongoing trials monitoring overlapping toxicities like cytopenia and ILD.
• Antibody-drug conjugates (ADCs) are demonstrating increasing efficacy in NSCLC, potentially shifting treatment paradigms in both second-line and first-line settings.
Advancements in NSCLC Treatment: Amivantamab, Perioperative Immunotherapy, and HER2-Targeted ADCs
• Amivantamab plus chemotherapy was approved for EGFR exon 19 deletions or exon 21 L858R substitution mutations in advanced NSCLC after progression on EGFR TKIs.
• Perioperative durvalumab and nivolumab have been approved for resectable NSCLC, expanding treatment options for patients without EGFR or ALK alterations.
• Fam-trastuzumab deruxtecan-nxki (T-DXd) is emerging as a significant option for HER2-mutated NSCLC, potentially shifting to frontline settings.
• Ongoing research explores optimizing checkpoint inhibitor use in the perioperative setting, particularly for patients achieving complete pathologic response.
© Copyright 2025. All Rights Reserved by MedPath